Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 3 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Low muscle strength, BMI in young males predict eventual ALS

07 Feb 2018

In healthy, young males, low muscle strength, body mass index (BMI) and erythrocyte volume fraction predict amyotrophic lateral sclerosis (ALS) later in life, a recent study has shown.

The researchers performed a prospective cohort study on 1,819,817 young males with an average age of 18.3±0.7 years. Over the 46-year follow-up period, 526 participants were diagnosed with ALS. The median age at first diagnosis was 50.0 years.

Baseline BMI was significantly lower in those who eventually developed ALS than in those who did not (21.9±3.0 vs 21.1±2.5 kg/m2; p=0.03). Difference in baseline muscle strength also showed a trend toward significance, wherein low muscle strength was more common in those who developed ALS later in life (p=0.06 for trend).

Mean erythrocyte volume fraction was likewise significantly lower in those who developed ALS than in those who did not (46.4±2.4 percent vs 46.2±2.5 percent; p=0.05).

The same trends were observed in a multivariate logistic regression model adjusted for potential confounders. For instance, BMI (hazard ratio [HR], 0.96; 95 percent CI, 0.93–0.99) remained a significant predictor of eventual ALS. Erythrocyte volume fraction was also significantly correlated with the risk of ALS (HR, 0.96; 0.92–0.998).

Finally, relative to high muscle strength at baseline, low muscle strength was likewise significantly predictive of ALS development later in life (HR, 1.36; 1.01–1.83).

In contrast, there appears to be no correlation between the risk of eventual ALS and erythrocyte sedimentation rate, physical fitness at baseline, parental education or psychiatric disorders.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 3 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.